Active substance
Methazolamide
- US FDA 9
- Health Canada 1
- US price lines 2
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| METHAZOLAMIDE | 25MG; 50MG | tablet · oral | ANI PHARMS | Prescription | 30 Jun 1993 |
| METHAZOLAMIDE | 25MG; 50MG | tablet · oral | CHARTWELL RX | Prescription | 30 Jun 1993 |
| METHAZOLAMIDE | 25MG; 50MG | tablet · oral | PHARMOBEDIENT | Prescription | 27 Jan 1994 |
| METHAZOLAMIDE | 25MG; 50MG | tablet · oral | BAUSCH AND LOMB INC | Prescription | 5 Oct 2018 |
| METHAZOLAMIDE | 25MG; 50MG | tablet · oral | TAGI | Prescription | 18 Oct 2022 |
| METHAZOLAMIDE | 25MG; 50MG | tablet · oral | AJANTA PHARMA LTD | Prescription | 9 Feb 2026 |
| NEPTAZANE | 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | LEDERLE | Discontinued | 26 Jan 1959 |
| METHAZOLAMIDE | 25MG; 50MG | tablet · oral | PHARMOBEDIENT | Discontinued | 28 Aug 1996 |
| METHAZOLAMIDE | 25MG; 50MG | tablet · oral | APPLIED ANAL | Discontinued | 17 Jul 1997 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| METHAZOLAMIDE | 02245882 | 50 MG | TABLET · ORAL | AA PHARMA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | METHAZOLAMIDE 25 MG TABLET | $0.62747 | per EA | 23 Sep 2026 |
| US NADAC | METHAZOLAMIDE 50 MG TABLET | $1.46836 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.